Summary:
Alkem Laboratories’ family trust sold 597,825 shares worth ₹301.9 crore to four domestic mutual funds. Q2 FY27 revenue rose 13.8%, but reported profit fell 11.7%. Domestic growth, R&D spending, newer-business performance and Daman remediation remain key investor-monitoring points.
A family trust has sold 0.5% of Alkem at ₹5,050 a share. Domestic mutual funds absorbed the stock, while the company’s operating outlook remains tied to domestic growth, new-business spending and US regulatory progress.
Alkem Laboratories came into focus after Sarandhar Singh, acting for the Samprada & Nanhamati Singh Family Trust, sold 597,825 shares on 17 November 2026. The transaction, worth about ₹301.9 crore, represented roughly 0.5% of the drugmaker’s equity. DSP Mutual Fund, Nippon India Mutual Fund, HDFC Mutual Fund and ICICI Prudential Mutual Fund were reported as buyers at ₹5,050 per share. It was a change in ownership, not fresh capital raised by Alkem.
₹301.9 Crore Trade Transfers 0.5% Ownership, Not Cash to Alkem
The promoter-linked trust received the sale proceeds, not the company. Alkem’s share count, debt and cash position do not change because of this secondary-market transaction.
The trust was reported to hold 18.29% before this sale. Subtracting approximately 0.5 percentage points suggests a holding near 17.79% immediately after the trade, subject to confirmation through the next shareholding disclosure. The transaction does not, on the available information, establish any change in managerial control or board representation.
The reported deal price of ₹5,050 was about 2.4% below the stock’s 17 November closing price of ₹5,175. That comparison describes the two published prices; it is not proof that every buyer received an equivalent discount to the prevailing market at the exact time of execution.
Four Domestic Mutual Funds Bought the Block as Promoter Selling Continued
The buyers were DSP, Nippon India, HDFC and ICICI Prudential mutual funds. Institutional participation helped absorb the supply, but it should not be read as a consensus forecast of a share-price rally.
This was also not the first promoter-family transaction of 2026. In June, the same trust sold 550,000 shares at ₹5,200 apiece, while promoter-group member Jayanti Sinha exited a roughly 1.04% stake. The November trade therefore belongs in a longer ownership-rebalancing pattern, although the family’s underlying motivation has not been publicly established in the material reviewed.
For investors, repeated sales are worth tracking through the next quarterly shareholding pattern. The more useful questions are whether promoter ownership continues to decline, whether purchases increase institutional concentration and whether any subsequent disclosure indicates a strategic shift. There is no basis to label the sale a warning about undisclosed earnings.
Q2 Revenue Grew 13.8%, but EBITDA Margin Slipped 50 Basis Points
Alkem’s latest quarter showed solid top-line growth with weaker operating leverage. Revenue reached ₹4,552 crore, while EBITDA rose 11.3% to ₹1,025 crore, below the pace of sales growth.
EBITDA margin was 22.5%, against 23.0% a year earlier. The company attributed the decline mainly to operating costs at its Enzene CDMO business and the Occlutech acquisition. Gross margin, by contrast, expanded about 220 basis points to 67.2%. This combination matters: the pressure did not originate from gross profitability alone; investment in newer businesses also absorbed part of the gain.
| Metric | Q2 FY27 | Q2 FY26 |
| Revenue from operations | ₹4,552 cr | ₹4,001 cr |
| EBITDA | ₹1,025 cr | ₹921 cr |
| EBITDA margin | 22.5% | 23.0% |
| PAT attributable to owners* | ₹675 cr | ₹765 cr |
*Company-reported PAT after non-controlling interests, rounded; the statutory consolidated profit figure may differ depending on attribution.
₹675 Crore Profit Fell 11.7% Despite Better Gross Margins
Profit attributable to owners declined 11.7% year on year to approximately ₹675 crore. Management identified a higher effective tax rate as the main reason for the decline.
This explains why a 14% revenue increase did not translate into higher reported earnings. The quarter also carried elevated R&D expenditure: ₹195 crore, or 4.3% of revenue, against ₹130 crore, or 3.3%, a year earlier. Those expenses support future products but reduce near-term profit conversion. The market’s concern should centre on whether the spending builds earnings capacity rather than the simple fact of promoter selling.
India Sales Rose 9.5%, While Chronic Therapies Grew 22.4%
The domestic business remained Alkem’s main earnings anchor. India sales increased 9.5% to roughly ₹3,028 crore, accounting for about two-thirds of consolidated revenue.
Its branded business grew 12.1%, while trade generics delivered mid-single-digit growth. Chronic therapies advanced 22.4%, ahead of the reported 16.0% market growth in that category. That shift is strategically useful for a company traditionally associated with acute therapies, where demand can vary with seasonal disease incidence.
Alkem also reported 26 product launches in the first half and continued expansion into semaglutide and other chronic-care products. The relevant test is whether new launches improve prescription depth and sustainable profitability, not merely the count of launches.
₹4,905 Crore Net Cash Offers Capacity to Fund New Businesses
Alkem reported net cash of ₹4,905 crore at 30 September 2026. The balance sheet offers a buffer as the group spends on biologics, medical technology and research.
That cash position is more relevant to the company than the promoter family’s ₹302 crore share-sale proceeds. It also makes the next phase of capital allocation measurable. Enzene and Occlutech need to demonstrate scale and a clearer path to positive operating contribution; without that, investment costs may continue to offset progress in the core formulations business.
The US business remains another variable. The company reported that its Daman formulations facility had received an Official Action Indicated classification from the US FDA in August 2026, with remediation underway.At ₹5,175 a Share, Buyers Are Paying for More Than Domestic Growth
At the 17 November close, Alkem was valued at about ₹61,900 crore using approximately 11.95 crore outstanding shares. Against quarterly attributable profit of ₹675 crore annualised mechanically, that implies roughly 23 times earnings. This is an illustrative run-rate calculation, not a trailing-12-month P/E or a forecast.
The multiple leaves room for steady domestic growth, but it also assumes that newer businesses will eventually contribute rather than permanently depress margins.
Investors should watch the next promoter-holding disclosure, domestic chronic growth, Enzene and Occlutech losses, US FDA remediation and whether EBITDA margin recovers toward management’s indicated 20–21% full-year range. Those developments carry far more weight than a single day’s transfer of 0.5% equity.









